Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 23;12(9):2387.
doi: 10.3390/cancers12092387.

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: Learning Curve Based on Surgical and Oncological Outcomes

Jerzy Mielko  1 , Karol Rawicz-Pruszyński  1 , Katarzyna Sędłak  1 , Katarzyna Gęca  1 , Magdalena Kwietniewska  1 , Wojciech P Polkowski  1
Affiliations

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: Learning Curve Based on Surgical and Oncological Outcomes

Jerzy Mielko et al. Cancers (Basel). .

Abstract

Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a complex, highly specialized procedure used to treat peritoneal surface malignancies (PSM) [...].

Keywords: CRS + HIPEC; learning curve; peritoneal surface malignancies.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Risk-adjusted sequential probability ratio test (RA-SPRT) chart for incomplete cytoreduction (CCR 2/3 procedures). The x-axis represents the operation number. The y-axis represents a cumulative log-likelihood ratio value.
Figure 2
Figure 2
Risk-adjusted sequential probability ratio test (RA-SPRT) chart for complications according to the Clavien–Dindo classification. The x-axis represents the operation number. The y-axis represents a cumulative log-likelihood ratio value.
Figure 3
Figure 3
Risk-adjusted sequential probability ratio test (RA-SPRT) chart for complications according to comprehensive complication index (cut off value = 40). The x-axis represents the operation number. The y-axis represents a cumulative log-likelihood ratio value.
Figure 4
Figure 4
Moving average of estimated risk of complications according to comprehensive complication index (cut off 40). The x-axis represents the operation number.
Figure 5
Figure 5
Moving average plot for length of stay (LOS). The x-axis represents the operation number. In all subsequent cases after arrow, the moving average (MA) of LOS is below 10 days.
See this image and copyright information in PMC

References

    1. Narasimhan V., Das A., Warrier S., Lynch C., McCormick J., Tie J., Michael M., Ramsay R., Heriot A. Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: Analysis of 384 consecutive cases. Langenbecks Arch Surg. 2019;404:527–539. doi: 10.1007/s00423-019-01805-x. - DOI - PubMed
    1. Shachar Y., Adileh M., Keidar A., Eid L., Hubert A., Temper M., Azam S., Beny A., Grednader T., Khalaileh A., et al. Management of inguinal involvement of peritoneal surface malignancies by cytoreduction and HIPEC with inguinal perfusion. J. Cancer. 2015;6:243–246. doi: 10.7150/jca.10325. - DOI - PMC - PubMed
    1. Ben-Yaacov A., Nizri E., Lahat G., Berger Y., Sadot E., Lavi R., Zippel D., Sebbag G., Avital I., Hoffman A., et al. Treatment of Peritoneal surface malignancies with cytoreductive surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC): Experience in Israel. Indian J. Surg. Oncol. 2019;10:19–23. doi: 10.1007/s13193-019-00874-0. - DOI - PMC - PubMed
    1. Votanopoulos K.I., Russell G., Randle R.W., Shen P., Stewart J.H., Levine E.A. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): Overview of 481 cases. Ann. Surg. Oncol. 2015;22:1274–1279. doi: 10.1245/s10434-014-4147-y. - DOI - PMC - PubMed
    1. Wong J.F., Tan G.H., Wang W., Soo K.C., Teo M.C. Repeat cytoreductive surgery and HIPEC for peritoneal surface malignancy and peritoneal carcinomatosis. World J. Surg. 2015;39:1578–1583. doi: 10.1007/s00268-015-2986-8. - DOI - PubMed

LinkOut - more resources